Back to Trades
Buy4
Avalyn Pharma Inc.
AVLN
Total Value
$5.0M
Net $5.0M bought
Purchases
$5.0M
1 transaction
Company Information
- Company Name
- Avalyn Pharma Inc.
- Ticker Symbol
- AVLN
- CIK
- 0001540171
Insider Information
- Name
- Carroll Jill
- Role
- Insider
- Location
- REDWOOD CITY, CA
Filing Details
- Filing Date
- May 1, 2026
- Transaction Date
- May 1, 2026
- Accession Number
- 0001193125-26-201894
- Form Type
- 4
- Net Trading Amount
- $5.0M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| May 1, 2026 | Common Stock | 1,419,298 | — | C | — |
| May 1, 2026 | Common Stock | 489,486 | — | C | — |
| May 1, 2026 | Common Stock | 277,778 | $18.00 | Purchase | $5.0M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| May 1, 2026 | Derivative | 27,309,719 | — | C | — |
| May 1, 2026 | Derivative | 9,418,561 | — | C | — |
Footnotes
- (F1)On May 1, 2026, each share of Series C-1 Convertible Preferred Stock (the "Series C-1 Preferred Stock") automatically converted into shares of Common Stock on a one-for-19.2417 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had no expiration date.
- (F2)The securities are directly held by SR One Capital Fund II Aggregator, LP ("SR One Fund II Aggregator"). SR One Capital Partners II, LP ("SR One Partners II") serves as the general partner of SR One Fund II Aggregator, and SR One Capital Management, LLC serves as the general partner of SR One Partners II. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Fund II Aggregator, and a limited partner of SR One Partners II. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
- (F3)On May 1, 2026, each share of Series D Convertible Preferred Stock (the "Series D Preferred Stock") automatically converted into shares of Common Stock on a one-for-19.2417 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The Series D Preferred Stock had no expiration date.